KIFC1 Overexpression Promotes Pancreatic Carcinoma Progression via Stabilising BUB1B
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70767 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Ao Cui und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Kinesins, Pancreatic Neoplasms, Gene Expression Regulation, Neoplastic, Protein Serine-Threonine Kinases. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Incubation Project, The Second Affiliated Hospital of Nanchang University, Foundation of Jiangxi Educational Commission, The Natural Science Foundation of Jiangxi Province.
Abstract (Originalsprache)
Pancreatic cancer (PC) is a highly lethal tumour of the gastrointestinal tract. New molecular targets are urgently needed for its treatment. Kinesin family member C1 (KIFC1) is implicated in the development and progression of several types of cancer. Previous studies from our group demonstrated that KIFC1 overexpression in hepatocellular carcinoma promotes malignant behaviours via the PI3K/AKT pathway. However, the molecular and functional mechanisms of KIFC1 in PC are not yet fully elaborated. In this study, KIFC1 and BUB1B were significantly upregulated in PC patient samples, and high KIFC1 expression was closely associated with the malignant phenotype and poorer overall survival (OS) in PC patients. Functional experiments showed that KIFC1 knockdown inhibited PC cell growth in vivo and in vitro, blocked cell cycle progression and hindered cell migration and invasion. In addition, rescue experiments showed that KIFC1 induced PC cell malignant behaviours dependent on BUB1B. Mechanistically, KIFC1 regulates BUB1B expression by competitively binding to BUB1B and reducing its ubiquitination and degradation. We have shown for the first time the molecular regulatory mechanism between KIFC1 and BUB1B on PC. Therefore, KIFC1 shows promise as an attractive therapeutic target for PC in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
- Jiangxi Province Key Laboratory of Molecular Medicine, Nanchang, China.
- Department of Neurology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
- Department of General Surgery, The People's Hospital of Gongqingcheng, Gongqingcheng, China.
- Department of Otorhinolaryngology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
ORCID-Profile: Ao Cui
Förderung
- Scientific Research Incubation Project, The Second Affiliated Hospital of Nanchang University
- Foundation of Jiangxi Educational Commission
- The Natural Science Foundation of Jiangxi Province
- The National Natural Science Foundation of China
- National Natural Science Foundation of China
Zitieren
APA
Cui, A., Yu, Y. X., Xiong, M. X., Wang, J. Y., Zou, Y. Q., Zhu, Y. Q., Ran, L. J., Zhang, Y., Liu, R. X., Dong, M. Y., Wang, H., Fang, L., & Fu, X. W. (2025). KIFC1 Overexpression Promotes Pancreatic Carcinoma Progression via Stabilising BUB1B. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70767
Vancouver
Cui A, Yu YX, Xiong MX, Wang JY, Zou YQ, Zhu YQ, et al. KIFC1 Overexpression Promotes Pancreatic Carcinoma Progression via Stabilising BUB1B. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70767
BibTeX
@article{Cui2025,
author = {Cui, Ao and Yu, Ying-Xue and Xiong, Mei-Xue and Wang, Ji-Yang and Zou, Ye-Qing and Zhu, Ya-Qiong and Ran, Long-Jian and Zhang, Yu and Liu, Rui-Xiang and Dong, Ming-Yi and Wang, Hui and Fang, Lu and Fu, Xiao-Wei},
title = {KIFC1 Overexpression Promotes Pancreatic Carcinoma Progression via Stabilising BUB1B},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70767}
}
EUVIMED